Ipilimumab and Gemcitabine for Advanced Pancreatic Cancer: A Phase Ib Study

BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) remains resistant to chemotherapy and immunotherapy individually because of its desmoplastic stroma and immunosuppressive tumor microenvironment. Synergizing cytotoxic T‐lymphocyte–associated antigen 4 (CTLA‐4) immune checkpoint blockade with chemo...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Oncologist
Glavni autori: Kamath, Suneel D., Kalyan, Aparna, Kircher, Sheetal, Nimeiri, Halla, Fought, Angela J., Benson, Al, Mulcahy, Mary
Format: Artigo
Jezik:Inglês
Izdano: John Wiley & Sons, Inc. 2019
Teme:
Gastrointestinal Cancer
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7216436/
https://ncbi.nlm.nih.gov/pubmed/31740568
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2019-0473
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items